Clinical Relevance of Small Airways Disease in Severe Asthma Patients Treated With Anti-InterLeukin-5 Therapy (SAIL)

Medical Centre Leeuwarden

Status: Enrolling

Conditions: Asthma

Study type: Observational

Funder types: Other

Identifiers

NCT05706597

SAIL2022

Details and patient eligibility

About

The aim of this research is to investigate the extent and clinical relevance of small airways disease in severe eosinophilic asthma patients treated with anti-IL5/5R therapy.

Enrollment: 110 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe asthma patients treated with anti-IL5/5R therapy (i.e. mepolizumab, benralizumab, reslizumab) for at least 4 months.

Exclusion criteria

• No information about lung function at baseline, or after both 4 months and 12 months.
• No information about clinical response (i.e. number of exacerbations, reduction of mOCS/ maintenance oral corticosteroid dose, ACQ, AQLQ) after both 4 months and 12 months.
• Treatment with another anti-IL5/5R therapy before